News

The Q&A document "Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products", which was prepared jointly by the EMA and the CMDh, has been updated once again and published in the new revision 22 on the EMA website.

More

A US company received a Warning Letter because of problems at their CMO. FDA points out that companies should have a robust qualification process for CMOs.

More

The guideline 'Additional guidance on the assessment on the risk assessment for presence of N-nitrosamines in APIs', first published in February 2020, has now been revised by a subgroup of the 'APIC Nitrosamines Task Force' and recently published in its latest version on the APIC website. The document is now called 'Nitrosamine Risk Management: Guidance for API Manufacturers' and has been extensively updated.

More

A Warning Letter was issued to a Dutch company, also because root cause determinations and CAPAs were deemed inadequate.

More

The FDA found serious GMP deficiencies during an inspection of a Chinese pharmaceutical manufacturer in November 2024. These include, above all, inadequate hygiene and ensuring the sterility of the products. For example, medicinal products were labelled as 'sterile' although neither sterilisation nor sterility tests were carried out.

More

The draft guideline "STABILITY TESTING OF DRUG SUBSTANCES AND DRUG PRODUCTS" of the ICH was published in April 2025 and is now available for public comment.

More

In November 2024, the US FDA inspected a French sterile manufacturer of prescription and OTC medicines. The inspectors found significant GMP violations. Deficiencies were cited in the handling of complaints, the microbiological control of aseptic processes and the cleaning and maintenance of production equipment.

More

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to a Chinese OTC manufacturer, highlighting CGMP deficiencies in raw material testing, process controls, stability testing, and quality oversight.

More

In a recent Warning Letter, the FDA outlines severe GMP deficiencies in the manufacture of OTC hand sanitizers and antibacterial soaps, including missing identity testing, lack of stability data, and absent process validation. Critical raw materials such as glycerin and ethanol were accepted without proper testing – despite their known risk of contamination with diethylene glycol (DEG), ethylene glycol (EG), or methanol, substances that have caused fatal poisoning incidents worldwide.

More

The FDA recently issued Warning Letters to several pharmaceutical companies for violating CGMP regulations and expectations on Quality Oversight.

More
x